CMED Initiates Dialogue on Review of Drug Pricing Rules
QR Group analyzes the impacts of the proposal on the pharmaceutical sector and how companies can prepare for the new regulatory scenario The Drug Market Regulation Chamber (CMED), linked to ANVISA, announced in July 2025 the start of a structured dialogue with the regulated sector to discuss the revision of drug pricing rules in Brazil. […]
CMED Opens Directed Consultation on Pricing of Advanced Therapies
QR Group analyzes regulatory impacts and what companies need to consider in the commercialization of gene, cell and tissue therapies The Drug Market Regulation Chamber (CMED) has started a targeted consultation on the pricing of advanced therapies — such as gene, cell, and tissue therapies. The measure aims to receive contributions from the regulated sector, […]
